LEGACY HERITAGE FUND DONATION LAUNCHES UNIQUE TEN-YEAR MEDICAL RESEARCH DEVELOPMENT PROJECT IN ISRAEL

The Legacy Heritage Clinical Research Institute at Rambam (LHCRIR), recently established through the generosity of the Legacy Heritage Fund, has jumpstarted Rambam's plan to build a Biomedical Discovery Tower whose core activity will be dedicated to clinically relevant research and discovery.

The LHCRIR mission is to perform excellent clinical studies -- aimed at understanding the causes of, and potentially curing, human diseases -- in a number of priority areas including, among others, cancer; cardiovascular disease and thrombosis; diabetes, metabolic and kidney disease; inflammatory, infectious and immune disease; neurodegenerative diseases; medical-device and imaging technology; and translational genetics. This activity will complement Rambam's outstanding and highly intensive provision of medical care to Northern Israel's residents and, in addition, will benefit from our proximity to the exceptional basic-science, human and physical resources of the Technion – Israel Institute of Technology.

The Legacy Heritage Fund grant and matching funds will be utilized for 3 related purposes: first and foremost, to attract and recruit on a competitive basis talented and promising research-oriented physicians at various levels of career development; to provide them with the finest laboratory and research infrastructure; and to seed their investigations with intramural research-operating support.   Successful applicants will have appointments to clinical departments at Rambam Health Care Campus and are also expected to be cross-appointed to the Technion's adjacent Rappaport Faculty of Medicine.

Established clinician-scientists at Rambam have been asked to spearhead recruitment from throughout Israel and internationally of the most gifted clinician-scientists to lead programs in the prioritized thematic areas of inquiry. The aim is to build a critical mass of research activity necessary for developing Centers of Excellence that will enable patient-oriented research discovery.

Next Article